Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thalidomide--a dreaded drug with new indications].

A Waage1, C Seidel

  • 1Hematologisk seksjon Medisinsk avdeling Regionsykehuset i Trondheim 7006 Trondheim. anders.waage@medisin.ntnu.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|November 22, 2001
PubMed
Summary

Thalidomide, once a sleeping pill, now shows efficacy in treating erythema nodosum leprosum, aphthous stomatitis, and advanced multiple myeloma. Its use in other cancers is not supported by current research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Neuroprotection in radiotherapy of brain metastases - a European pattern-of-care analysis by the ESTRO CNS Focus group.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Stereotactic radiotherapy for spinal and non-spinal bone metastases: a patterns-of-care analysis in German-speaking countries as part of a project of the interdisciplinary Radiosurgery and Stereotactic Radiotherapy Working Group of the DEGRO/DGMP.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

Short-term survivors with brain metastases have modest benefits from focal and systemic therapies and remain frequent despite improving treatment landscape.

Clinical and translational radiation oncology·2025
Same author

Instrumental activities of daily living in neuro-oncology: International validation of the EORTC IADL-BN32 questionnaire.

European journal of cancer (Oxford, England : 1990)·2024
Same author

High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT.

ESMO open·2024

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Thalidomide was initially marketed as a safe sedative in the 1950s.
  • Its teratogenic effects led to withdrawal in 1961 due to severe birth defects.
  • Modern research explores its therapeutic potential beyond its historical context.

Observation:

  • Thalidomide exhibits significant immunoregulatory properties in vitro.
  • It has demonstrated efficacy in treating conditions like erythema nodosum leprosum and aphthous stomatitis.
  • Experimental studies show thalidomide inhibits angiogenesis, suggesting anticancer applications.

Findings:

  • Thalidomide is effective for erythema nodosum leprosum and aphthous stomatitis.
  • A notable response rate of over 30% is observed in patients with advanced or resistant multiple myeloma.

Related Experiment Videos

  • Clinical trials indicate no benefit of thalidomide for breast cancer or glioma patients.

    • Implications:

    • Thalidomide's immunomodulatory and anti-angiogenic effects support its use in specific immunological and oncological conditions.
    • Its application in advanced multiple myeloma represents a significant therapeutic advancement.
    • Careful patient selection is crucial, as thalidomide is not effective for all cancer types.